Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis (ULTRA)
研究概览
详细说明
This is an open-lable, single arm study of the ultrasonographic monitoring of response to infliximab in patients with rheumatoid arthritis. Approximately 120 subjects will be enrolled. Subjects will receive infliximab 3mg/kg intravenous infusion at 0, 2, 6 week, and then repeated every 8 weeks until 24 weeks.
The efficacy assessment is observed by ACR response, HAQ, DAS28, sharp scores and US assessment at 0,2,6,14, 22, and 24weeks and ultrosonographic and radiographic assessments are conducted at 0, 6,and 24weeks.
Subjects will be followed for AEs and SAEs up to 8 weeks following the last study treatment administration (see Section 6).
The end of study is defined as the time the last subject completes the 24 weeks visit.
研究类型
注册 (预期的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
Beijing
-
Beijing、Beijing、中国、100000
- 招聘中
- Perking Union Medical College Hospital
-
接触:
- Xiaomei Leng, MD
- 电话号码:+86-13681057089
- 邮箱:lengxm@gmail.com
-
首席研究员:
- Xiaomei Leng, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- age 18-65 years, male or female and who are capable of providing informed consent, which must be obtained prior to any study-related procedures.
- Those who have a definitive diagnosis of RA based on the criteria of American College of Rheumatology in 1987 and have moderate to severe disease (DAS28 more than 3.2).
- Patients using oral corticosteroids, must have been on a stable dose of prednisone 10mg/day or its equivalent for at least 4 weeks prior to screening. If currently not using corticosteroids the patient must have not received corticosteroids for at least 4 weeks prior to screening.
- Patients using DMARDs, must have been on a stable dose for at least 12 weeks prior to screening. If currently not using DMARDs the patient must have not received DMARDs for at least 12 weeks prior to screening.
- If using NSAIDs or other analgesics for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent.
Exclusion Criteria:
- Patient who has a known hypersensitivity to human immunoglobulin proteins or other components of infliximab.
- Patient who suffers from systemic inflammatory disease whose signs and symptoms are expected to affect the evaluation of the study drug.
- Patient who has a history of receiving infliximab or any other biologics.
- Patient who has stage IV RA.
- Patient who has had or is on live viral or bacterial vaccinations within 4 weeks to study entry.
- Patient who ever suffered from chronic or recurrent infection, including but not limited to: chronic kidney infection, chronic thoracic cavity infection (eg. bronchiectasis), nasosinusitis, recurrent urinary tract infection, open, drain or dermal infected wound.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The primary objective of this study is to evaluate the efficacy of treatment with infliximab on synovitis in RA patients using ultrasonography at 24 weeks.
大体时间:24 weeks
|
24 weeks
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
estimate and visualize the efficacy of treatment with infliximab in RA patients using ultrasonography
大体时间:6, 24 weeks
|
6, 24 weeks
|
|
investigate the validity and sensitivity of ultrasonography assessment of joints inflammation in patients with RA compared with sharp scores
|
|
|
3) observe the relationship between ultrasonography assessment and DAS28, ACR20 and sharp scores and other clinical index
|
合作者和调查者
合作者
调查人员
- 首席研究员:Yan Zhao, MD、Perking Union Medical College Hospital
- 首席研究员:Xiaomei Leng, MD、Perking Union Medical College Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.